Citi Pharma Limited (PSX:CPHL)
Pakistan · Delayed Price · Currency is PKR 61.66
-0.38 (-0.61%)
At close: Oct 16, 2026
Citi Pharma Ratios and Metrics
Market cap in millions PKR. Fiscal year is July - June.
Millions PKR. Fiscal year is Jul - Jun.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 15, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
| 14,087 | 17,790 | 19,184 | 6,511 | 4,875 | 7,457 | |
Market Cap Growth | -35.14% | -7.26% | 194.63% | 33.55% | -34.62% | - |
Enterprise Value | 16,838 | 21,032 | 20,807 | 6,236 | 4,443 | 5,627 |
Last Close Price | 62.04 | 77.87 | 80.81 | 25.42 | 17.15 | 26.24 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 15, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
PE Ratio | 17.93 | 22.51 | 21.51 | 7.81 | 7.41 | 11.41 |
Forward PE | - | 18.68 | 14.23 | 6.55 | 6.34 | - |
PS Ratio | 1.01 | 1.26 | 1.46 | 0.53 | 0.39 | 0.76 |
PB Ratio | 1.31 | 1.64 | 1.77 | 1.16 | 0.91 | 1.58 |
P/TBV Ratio | 1.31 | 1.64 | 1.77 | 1.16 | 0.91 | 1.58 |
P/FCF Ratio | - | - | - | 8.46 | - | - |
P/OCF Ratio | 87.46 | 109.78 | - | 4.87 | - | - |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 15, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
EV/Sales Ratio | 1.20 | 1.49 | 1.58 | 0.50 | 0.36 | 0.57 |
EV/EBITDA Ratio | 7.89 | 9.90 | 11.78 | 4.65 | 3.53 | 5.28 |
EV/EBIT Ratio | 8.72 | 10.84 | 12.97 | 5.17 | 3.81 | 5.66 |
EV/FCF Ratio | - | - | - | 8.11 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 15, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Debt / Equity Ratio | 0.29 | 0.29 | 0.27 | 0.26 | 0.34 | 0.20 |
Debt / EBITDA Ratio | 1.44 | 1.44 | 1.66 | 1.08 | 1.46 | 0.88 |
Debt / FCF Ratio | - | - | - | 1.89 | - | - |
Net Debt / Equity Ratio | 0.25 | 0.25 | 0.13 | 0.01 | 0.05 | -0.22 |
Net Debt / EBITDA Ratio | 1.30 | 1.30 | 0.77 | 0.03 | 0.21 | -0.99 |
Net Debt / FCF Ratio | -5.05 | -5.05 | -2.89 | 0.05 | -0.20 | 1.14 |
Asset Turnover | 0.77 | 0.77 | 0.88 | 1.16 | 1.37 | 1.34 |
Inventory Turnover | 3.04 | 3.04 | 3.12 | 3.72 | 5.06 | 6.82 |
Quick Ratio | 0.58 | 0.58 | 0.66 | 0.68 | 0.80 | 1.15 |
Current Ratio | 1.25 | 1.25 | 1.30 | 1.36 | 1.48 | 1.86 |
Return on Equity (ROE) | 7.28% | 7.28% | 10.81% | 15.14% | 13.05% | 14.40% |
Return on Assets (ROA) | 6.61% | 6.61% | 6.71% | 7.03% | 8.06% | 8.49% |
Return on Invested Capital (ROIC) | 8.21% | 8.84% | 11.81% | 13.88% | 17.27% | 23.24% |
Return on Capital Employed (ROCE) | 17.20% | 17.20% | 14.40% | 20.60% | 21.10% | 19.40% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 15, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Earnings Yield | 5.58% | 4.44% | 4.65% | 12.80% | 13.50% | 8.77% |
FCF Yield | -3.84% | -3.06% | -2.45% | 11.82% | -26.33% | -12.38% |
Dividend Yield | 5.68% | - | 4.17% | 11.40% | 11.71% | - |
Payout Ratio | 101.25% | 101.25% | 82.94% | 68.53% | - | 47.66% |
Buyback Yield / Dilution | - | - | - | - | -0.70% | -21.65% |
Total Shareholder Return | 5.64% | - | 4.17% | 11.40% | 11.01% | -21.65% |